<DOC>
	<DOCNO>NCT01767311</DOCNO>
	<brief_summary>This multinational , multicenter , double-blind , placebo-controlled , parallel-group study use Bayesian design response adaptive randomization across placebo 5 active arm BAN2401 determine clinical efficacy explore dose response BAN2401 use composite clinical score ( ADCOMS ) . BAN2401-G000-201 18-month study 3 dose level ( 2.5 , 5 , 10 mg/kg ) give biweekly ( every 2 week ) separate group participant 2 dose level ( 5 10 mg/kg ) give monthly separate group participant . Participants 2 clinical subgroup : mild cognitive impairment ( MCI ) due Alzheimer 's disease ( AD ) mild Alzheimer 's disease dementia . Frequent interim analysis conduct continually update randomization allocation basis primary clinical endpoint .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Efficacy BAN2401 Subjects With Early Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Key Inclusion Criteria Mild Cognitive Impairment due Alzheimer 's Disease Intermediate likelihood : 1 . Subjects meet National Institute Aging Alzheimer 's Association ( NIAAA ) core clinical criterion mild cognitive impairment due Alzheimer 's disease intermediate likelihood 2 . Subjects CDR score 0.5 Memory Box score 0.5 great Screening Baseline 3 . Subjects report history subjective memory decline gradual onset slow progression last one year Screening ; MUST corroborate informant Key Inclusion Criteria Mild Alzheimer 's Disease Dementia : 1 . Subjects meet NIAAA core clinical criterion probable Alzheimer 's disease dementia 2 . Subjects CDR score 0.51.0 Memory Box score 0.5 great Screening Baseline Inclusion Criteria must meet subject : 1 . Subjects objective impairment episodic memory indicate least 1 standard deviation ageadjusted mean Wechsler Memory Scale IV Logical Memory II ( WMSIV LMII ) : 1 . Less equal 15 age 50 64 year 2 . Less equal 12 age 65 69 year 3 . Less equal 11 age 70 74 year 4 . Less equal 9 age 75 79 year 5 . Less equal 7 age 80 90 year 2 . Positive amyloid load indicate PET CSF assessment 3 . Age 50 90 year , inclusive 4 . Mini Mental State Examination ( MMSE ) score equal great 22 , equal less 30 , Screening Baseline 5 . Body Mass Index ( BMI ) great 17 less 35 Screening 6 . Females must pregnant lactating , specify contraceptive precaution must follow 7 . Subjects acetylcholinesterase inhibitor memantine therapy Alzheimer 's disease ( AD ) must stable dose least 12 week prior baseline 8 . Subjects must identify caregivers/informants 9 . Subjects must provide write informed consent Key 1 . Any neurological condition may contribute cognitive impairment beyond cause subject 's AD 2 . History transient ischemic attack ( TIA ) , stroke , seizure within 12 month Screening 3 . Any psychiatric diagnosis symptom , ( e.g. , hallucination , major depression , delusion ) could interfere study procedure subject 4 . Contraindications MRI scanning , include cardiac pacemaker/ defibrillator , ferromagnetic metal implant , e , g. , skull cardiac device approve safe use MR scanner 5 . Evidence clinically significant lesion could indicate dementia diagnosis AD brain MRI Screening , significant pathological finding brain MRI Screening 6 . A prolonged QT/QTc interval ( QTc great 450 m ) demonstrate repeat electrocardiogram ( ECG ) 7 . Certain specified medical condition 8 . Severe visual hearing impairment would prevent subject perform psychometric test accurately</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>BAN2401</keyword>
</DOC>